With a 30 per cent revenue share, Europe trails the United States as the second largest regional market for therapeutic peptides. The rising need for new therapeutic approaches combined with the potential of peptides as active pharmaceutical ingredients for effective drug formulation is contributing to rapid market development.
Manufacturers will need, however, to demonstrate scale-up ability if they are to leverage emerging growth opportunities, according to Frost & Sullivan.
In 2003, Europe contributed an estimated US$ 300 million to the US$ 1.0 billion global therapeutic peptides market. Growing at a compound annual growth rate of 10.5 per cent over the 20032010 period, the region is poised to generate US$ 605.0 million in 2010.
With a 33 per cent share in 2003, Germany led the European therapeutic peptides market closely followed by the United Kingdom with a 30 per cent share. Other important markets included Scandinavia, France, Italy and Spain.
Motivated by the development of novel delivery techniques, innovative manufacturing technologies and vigorous R&D activities, many manufacturing, pharmaceutical and biotechnology companies have entered the market. Advances in genomics and proteomics have boosted demand for small peptide and peptidomimetic drugs even as human genome sequencing has provided further impetus to peptide research.
The persistent need for novel therapies in infectious, cardiovascular, oncology, metabolic disease, central nervous system (CNS) disorders and other therapeutic categories is providing a financial spur for the development of new peptide therapies.
The approval of new peptide-based drug products such as Fuzeon is stirring interest among many pharmaceutical companies with the entry of leading pharmaceuticals companies such as Roche and Merck being seen as a vindication of the market's strong growth potential.
Globally, more than 40 peptide-based products are commercially available with 6 in the registration process. In Europe, about four to six peptide based products are in the market, with 100 in the clinical stage and 150 in advanced pre-clinical phases. Recently approved new chemical entities and generics are set to expand the market in coming years.
Peptides used in drug formulation and clinical trials account for nearly 93 per cent of the European therapeutic peptides market with R&D comprising the remainder. Almost 60 per cent of the market comprises peptide-based therapeutics for the oncology segment followed by cardiovascular, infection and metabolic therapeutics.
biotech.frost.com
